Penilaian Erection Hardness Score Pasien Benign Prostatic Hyperplasia yang Ditangani dengan Tamsulosin dan Kombinasi Tamsulosin-Dutasteride

Joko Pitoyo, Bambang S Noegroho, Ricky Adriansjah

Abstract

The goal of Benign Prostate Hyperplasia (BPH) therapy is to relieve symptoms and maintain disease progression as well as the side effects of drugs and their benefits for improving the quality of life and sexual quality. This study aimed to assess the effect of tamsulosin therapy with combination therapy of tamsulosin and dutasteride on the erection hardness score (EHS) in men with LUTS due to BPH. This study is a cross-sectional study which assesses and compares differences in erection hardness scores (EHS) of patients with benign prostatic hyperplasia (BPH) before and after tamsulosin therapy and the combination of tamsulosin + dutasteride. After three months of therapy, the group of subjects given tamsulosin had an IPSS score of 12.87 (p=0.00), IIEF-5 15.43 (p=0.51), EHS 2.6 (p=0.08), while the tamsulosin + dutasteride group had an IPSS score 12.53(p=0.00), IIEF-5 15.83 (p=0.02), and EHS 2.6 (p=0.01). The decrease in EHS was more statistically significant in treatment with tamsulosin + dutasteride combination therapy compared with tamsulosin monotherapy, this was due to the effect of each drug combined.

Keywords

Benign Prostate Hyperplasia, Tamsulosin, Tamsulosin-Dutasteride

Full Text:

PDF

References

Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006 Apr;49(4): 651-8.

Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984 Sep;132(3):474-9.

Chute CG, Panser LA, et al. Prevalence of prostatism: a population based survey of urinary symptoms. J Urol 1993;150:85.

McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006; 97 (Suppl. 2): 23–8

British Society for Sexual Medicine. British Society for Sexual Medicine guidelines on the management of erectile dysfunction. BSSM, 2007. Available at www.bssm.org.uk/downloads/default.asp

Dunn K, Croft P, Hackett G. Sexual problems: a study of the prevalence and need for health care in the general population. Fam Pract 1998; 15 (6): 519–524.

Rosen R, Fisher W, Eardley I et al. The multinational Men’s Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20 (5): 607–617.

Allen D. Seftel. Erectile Dysfunction in the Elderly: Epidemiology, Etiology, and Approaches to Treatment. In: Male and Female Sexual Dysfunction. Elsevier Limited. 2004: 238

AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170: 530–47

Van Dijk MM, de la Rosette JJ, Michel MC. In: Effects of alpha(1)-adrenoceptor antagonists on male sexual function.

Giuliani F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int. 2006;97 Suppl 2:34-8.

Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003; 44: 82–8

AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170: 530–47

Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004; 46: 547–54

McConnell JD, Bruskewitz R, Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. New Engl J Med 1998; 338: 557–63

McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on clinical progression of benign prostatic hyperplasia. New Engl J Med 2003; 349: 2387–98

Roehrborn CG, Boyle P, Nickel JC et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434–41

Reilly CM, Stopper VS, Mills TM. Androgens modulate the alphaadrenergic responsiveness of vascular smooth muscle in the corpus cavernosum. J Androl 1997; 18: 26–31

Park KH, Kim SW, Kim KD, Paick JS. Effects of androgens on nitrite oxide mRNAs in rat corpus cavernosum. BJU Int 1999; 83: 327–33

Giuliano F, Clement P. Physiology of ejaculation: emphasis on serotonergic control. Eur Urol 2005; 48: 408–17

Giuliano F, Bernabé J, Droupy S, Alexandre L, Allard J. A comparison of the effects of tamsulosin and alfuzosin on neurally evoked increases in bladder neck and seminal vesicle pressure in rats. BJU Int 2004; 93: 605–8

Tambaro S, Ruiu S, Dessi C, Mangeau R, Marchese G, Pani L. Evaluation of tamsulosin and alfuzosin activity in the rat vas deferens: relevance to ejaculation delays. J Pharmacol Exp Ther 2005; 312: 710–7

Gerstenberg TC, Levin RJ, Wagner G. Erection and ejaculation in man. Assessment of the electromyographic activity of the bulbocavernosus and ischiocavernosus muscles. Br J Urol 1990; 65: 395–402

Clement P, Bernabe J, Kia HK, Alexandre L, Giuliano F. D2-like receptors mediate the expulsion phase of ejaculation elicited by 8-hydroxy-2-(di-N propylamino) tetralin (8-OH-DPAT) in rats. J Pharmacol Exp Ther 2006; 316: 830–4

Giuliano F, Bernabé J, Laurin M et al. Tamsulosin impairs bulbospongiosus muscle contractions induced by central injection of 8-OH-DPAT in anaesthetized rats while alfuzosin does not. J Urol 2005; 173 (Suppl.): 391, A1444

DOI: https://doi.org/10.26891/JIK.v16i1.2022.41-48

Refbacks

  • There are currently no refbacks.